Clinical Takeaway
Key GLP-1 policy developments affecting clinical prescribing and patient access.
GLP-1 Policy Watch
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →April 16, 2026
- GLP-1 Insurance Coverage Update: April 16, 2026
As of April 2026, twelve states mandate GLP-1 coverage for obesity, though commercial insurers and Medicare Part D plans often restrict access without diabetes diagnosis, requiring clinicians to verify formulary status.
Source: CMS / Formulary Tracker - Compounding GLP-1 Medications: Regulatory Status as of April 16, 2026
The FDA maintains semaglutide shortage status, permitting continued compounding while clinicians monitor weekly updates; tirzepatide compounding regulations differ and require separate verification.
Source: FDA Drug Shortage Database - Prior Authorization Burden for GLP-1 Prescriptions: April 16, 2026
CMS proposes expedited prior authorization standards for GLP-1 medications to reduce 11-day processing delays and 30% denial rates, improving timely access for diabetic and obese patients.
Source: American Medical Association
